My journey through changing Rheumatoid Arthritis (RA) medications 

New prescription, new hope – switch 

Matilda Swan 

Switch 

This word is so simple, yet so loaded for anyone living with chronic rheumatoid arthritis or many other auto immune diseases. For me, “switch” has meant not only new prescriptions, but new expectations, new side effects, new routines, and new hopes. 

I want to share my journey – through each new medication, each “switch,” guided by the careful advice of my rheumatologist after six monthly medical tests and procedures, during the past nine years of living with Rheumatoid Arthritis. 

The First Step: Cortisone and Plasmoquin (Hydroxychloroquine) 

When I was first diagnosed with Rheumatoid Arthritis, my life was dictated by pain and fatigue. My rheumatologist introduced cortisone to me as my first real weapon against the inflammation raging through my joints. Cortisone brought relief, and for a while, made me believe I could reclaim the life I once knew. But as many learn, steroids are not a long-term solution to manage RA, if there is progression of the illness. 

Hydroxychloroquine is an antimalarial agent with have several pharmacological actions which may be involved in their therapeutic effect in the treatment of rheumatic disease.  

But with this debilitating disease, I still very often need cortisone treatment when pain and inflammation wreak havoc through my body. And surely, I know, the disastrous side-effects is a dark and ominous cloud gathering overhead.  

During the Covid-19 epidemic, people thought that Plasmoquin was a defence strategy against the Covid virus, and chronic users suffered severely because of the unavailability of Plasmoquin tablets.  

Cortisone is a man-made version of a natural hormone called cortisol (corticosteroid hormone). It is a naturally occurring corticosteroid metabolite that is also used as a pharmaceutical prodrug. Cortisol decreases your body’s natural defensive response and reduces symptoms such as swelling and allergic-type reactions. This medication is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, and certain cancers.  

Switching to Salazopyrin (Sulfasalazine) 

The first major “switch” came, when my doctor suggested Salazopyrin (Sulfasalazine). I welcomed the change, eager to move off steroids. Salazopyrin was gentler in some ways, but my body wasn’t thrilled. I encountered persistent nausea and headaches, and the improvement to my joints was not as was expected. Sometimes it is just the way it is with a switch. Nothing is guaranteed. After months of trying, my rheumatologist and I agreed -it was time for another switch. 

Therapeutic benefit of sulfasalazine appears to be due to a local action of the sulfasalazine and its split product 5-aminosalicylic acid on the mucous membrane and deeper colonic structures.  

Switching to Methotrexate (Amethopterin): A New Chapter 

Methotrexate is often called the gold standard for the treatment of RA, and I approached it with a mixture of hope and trepidation. The weekly routine of taking those pills became a ritual. Some weeks, I felt stronger, almost normal; other weeks, the side effects – fatigue, mouth sores, stomach upset – reminded me I was far from “normal.” Blood tests became a regular companion, watching for changes in my liver function. And sure, enough, my liver was battered by Methotrexate. Eventually it was realized that the Methotrexate was not aiding my struggle with the effects of Rheumatoid Arthritis.  

Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases.  

Switch. Switch. Switch and Switch: Advanced Therapies – Biological injections: Humira (Adalimumab), Orencia (Abatacept), Actemra (Tocilizumab) and Unamity (Baricitinib) tablets. 

The next chapter brought me into the world of biologics.

Humiri was my introduction to self-injecting medication.  

Humiri

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). 

Next came Orencia injections. 

Orencia gave me energy, but only for a time. Eventually, my disease activity climbed once more.  

Orencia

Abatacept is a fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G1 (IgG1). Abatacept selectively modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28. 

Actemra followed 

I remember the first injection vividly – nervousness and cautious optimism. Actemra’s relief wasn’t permanent. I still have a bucket filled with syringes to show for my brave effort to challenge the symptoms of chronic rheumatoid arthritis! 

Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia. 

Unamity was the next promise of new hope.  

For a year Unamity was my silent chemical partner in the fight against the devastating effects of Rheumatoid Arthritis. I never truly know if Unamity had the desired effect, or did it just keep the status quo. During these months it felt as if I was carrying a heavy burden as in tons of bricks in my body. My blood pressure soared and I felt anxious. I experienced a bag full of side-effects.    

Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and >400 nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. 

Taking on Rheumatoid Arthritis with a big gun – Ristova (Rituximab) infusions 

The most recent switch suggested by the rheumatologist, was Ristova (Rituximab). Ristova required a different schedule, and the process felt more serious: pre-meds, careful monitoring, and long hospital days. The switch affects my body- it shapes my calendar, my work, my family’s routines. There is the terrible tiredness, the most excruciating headaches and my immune system dropped to the floor. Virus infections plague me without a break. Sometimes I think there is a moment of hope, but setbacks make me weary and despondent. Will this be a permanent switch? 

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas. 

Today I very well realise with a growing acceptance that switches are part of this journey. It may well be the ever changing “new-normal” for me and millions of others, struggling with chronic auto-immune diseases.  

What I’ve learned from switching 

Each switch is more than a clinical decision. It’s an emotional recalibration, a reckoning with uncertainty, a test of patience and trust. With every new medication, I’ve learned more about my body, about resilience, and about the power of partnership with my healthcare team. 

I’ve also learned to grieve each loss – of control, of stability – and to celebrate even the smallest wins. Switching isn’t a failure; it’s a sign that I’m still moving, still hoping, still fighting for a better quality of life. 

To anyone else facing the uncertainty of “switch,” know you’re not alone. Each new prescription is a new hope, and every chapter – no matter how difficult – moves your story forward. Keep “switching” when the medical diagnosis suggests changing your choice of medicine. We never know when the next prescription, the next switch, will bring long term help and stability.